Bisphosphonates for Prevention of Post-Denosumab Bone Loss
Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
The primary goal of the study is to assess the extent to which bisphosphonate therapy will
prevent decreases in bone mass that may occur after cessation of denosumab in premenopausal
women with idiopathic osteoporosis (IOP) enrolled in AAAN0161 (FD05114) "Denosumab for the
prevention of post-teriparatide bone loss in premenopausal women with idiopathic
osteoporosis".
In addition, the investigator will observe participants for a second year off bisphosphonate
therapy to assess duration of response.
The hypothesis is that bisphosphonate therapy with alendronate or zoledronic acid, initiated
after recovery of bone remodeling activity, will prevent significant bone loss after
discontinuing denosumab.